/
Oncology
Primary Central Nervous System Lymphoma
11
Pipeline Programs↗
7
Active Trials↗
10
Companies Involved↗
Primary Central Nervous System Lymphoma is an emerging landscape with 11 programs across 10 companies. The most active players are Ono Pharmaceutical Co. Ltd. 2 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 16
Phase 32
Approved
No programs
Analysis
Modality Breakdown
82%
Small molecule
9 of 11 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
9
clinical trials
Recruiting4 · 44%
Active, not recruiting2 · 22%
Completed1 · 11%
Not yet recruiting1 · 11%
Suspended1 · 11%
Clinical Trials
Trial Activity
9 trials
A Prospective, Open-label, Randomized Controlled Study Comparing Rituximab, Methotrexate, Cytarabine, and Penpulimab (R-MA-PD-1) Versus Rituximab, Methotrexate, and Cytarabine (R-MA) in Treatment-naive Patients With Primary Central Nervous System Lymphoma
Not yet recruiting·—·Preclinical·NCT07764601·58 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)